In the present study, elevated HER2 ECD levels were observed in 4.4% (126/2,862) of the primary breast cancer patients, which is a noteworthy finding because it was derived from a large number of patients at a single institute and using a single US FDA-approved assay. The gene discussed is ERBB2; the disease is breast cancer.